Phase 3Completed

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia

Sponsor
LG Life Sciences (Industry)
Enrollment
168 enrolled
Conditions
Hypertension,; Hyperlipidemia
Interventions
Valsartan 160mg; Rosuvastatin 20mg; Valsartan 160mg placebo; Rosuvastatin 20mg placebo
Ages
adults, older adults
Registry
NCT01918332

Full record on ClinicalTrials.gov

From the registry

This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.

Primary outcomes

  • sitDBP Changes at Week 8 From Baseline
  • LDL-C Percentage Changes at Week 8 From Baseline

History

  1. Results first posted

  2. Last registry update

  3. Registered

  4. Primary completion

  5. Started